Xlife Sciences AG / Key word(s): MiscellaneousXlife Sciences portfolio company launches project to research a potential therapy for amyotrophic lateral sclerosis (ALS) 16.01.2023 / 07:00 CET/CESTXlife Sciences' (SIX: XLS) portfolio company inflamed pharma has launched a research project to develop a potential th.
EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study resultsNewron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia 03.01.2023 / 07:00 CET/CESTThe issuer is solely responsible for the c.
Xlife Sciences AG / Key word(s): MiscellaneousPortfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies 01.12.2022 / 07:01 CET/CESTLysatpharma, a portfolio company of Xlife Sciences (SIX: XLS), and Novaxomx, a joint-venture of Xlife Scienc.
Xlife Sciences AG / Key word(s): Miscellaneousalytas therapeutics collaborates with spin-off from the German Diabetes Center 28.11.2022 / 07:00 CET/CESTXlife Sciences’ (SIX: XLS) portfolio company alytas therapeutics (located in Jena, Germany) explores innovative, antibody-based therapeutic concepts for treatment of.